<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:36:29Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7534806" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7534806</identifier>
        <datestamp>2020-10-06</datestamp>
        <setSpec>trials</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Trials</journal-id>
              <journal-id journal-id-type="iso-abbrev">Trials</journal-id>
              <journal-title-group>
                <journal-title>Trials</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1745-6215</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7534806</article-id>
              <article-id pub-id-type="pmcid">PMC7534806</article-id>
              <article-id pub-id-type="pmc-uid">7534806</article-id>
              <article-id pub-id-type="pmid">32854772</article-id>
              <article-id pub-id-type="pmid">32854772</article-id>
              <article-id pub-id-type="publisher-id">4675</article-id>
              <article-id pub-id-type="doi">10.1186/s13063-020-04675-7</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Study Protocol</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Rivaroxaban compared to no treatment in ER-negative stage Iâ€“III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Castle</surname>
                    <given-names>John</given-names>
                  </name>
                  <address>
                    <email>john.castle@manchester.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Blower</surname>
                    <given-names>Emma</given-names>
                  </name>
                  <address>
                    <email>emma.blower@manchester.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bundred</surname>
                    <given-names>Nigel J.</given-names>
                  </name>
                  <address>
                    <email>nigel.bundred@manchester.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harvey</surname>
                    <given-names>James R.</given-names>
                  </name>
                  <address>
                    <email>james.harvey@mft.nhs.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thachil</surname>
                    <given-names>Jecko</given-names>
                  </name>
                  <address>
                    <email>jecko.thachil@mft.nhs.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marshall</surname>
                    <given-names>Andrea</given-names>
                  </name>
                  <address>
                    <email>andrea.marshall@warwick.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cox</surname>
                    <given-names>Karina</given-names>
                  </name>
                  <address>
                    <email>karina.cox@nhs.net</email>
                  </address>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cicconi</surname>
                    <given-names>Silvia</given-names>
                  </name>
                  <address>
                    <email>s.cicconi@liverpool.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Holcombe</surname>
                    <given-names>Chris</given-names>
                  </name>
                  <address>
                    <email>chris.holcombe@rlbuht.nhs.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Palmieri</surname>
                    <given-names>Carlos</given-names>
                  </name>
                  <address>
                    <email>c.palmieri@liverpool.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Kirwan</surname>
                    <given-names>Cliona C.</given-names>
                  </name>
                  <address>
                    <email>cliona.kirwan@manchester.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.5379.8</institution-id><institution-id institution-id-type="ISNI">0000000121662407</institution-id><institution>Manchester Cancer Research Centre, </institution><institution>The University of Manchester, </institution></institution-wrap>Wilmslow Road, Manchester, M20 4GJ UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.417286.e</institution-id><institution-id institution-id-type="ISNI">0000 0004 0422 2524</institution-id><institution>The Nightingale Centre, </institution><institution>Wythenshawe Hospital, </institution></institution-wrap>Manchester, M23 9LT UK </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.419319.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0641 2823</institution-id><institution>Department of Haematology, </institution><institution>Manchester Royal Infirmary, </institution></institution-wrap>Manchester, M13 9WL UK </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.7372.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 8809 1613</institution-id><institution>Warwick Clinical Trials Unit, </institution><institution>University of Warwick, </institution></institution-wrap>Coventry, CV4 7AL UK </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.416304.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0398 7664</institution-id><institution>Department of Breast Surgery, </institution><institution>Maidstone Hospital, </institution></institution-wrap>Maidstone, ME16 9QQ UK </aff>
                <aff id="Aff6"><label>6</label>Cancer Research UK Liverpool Cancer Trials Unit, Liverpool, L69 3GL UK </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.269741.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0421 1585</institution-id><institution>Breast Unit, </institution><institution>Royal Liverpool and Broadgreen University Hospitals NHS Trust, </institution></institution-wrap>Liverpool, L3 9TA UK </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.10025.36</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8470</institution-id><institution>Department of Molecular and Clinical Cancer Medicine, </institution></institution-wrap>Liverpool, L69 3GA UK </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>27</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>27</day>
                <month>8</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2020</year>
              </pub-date>
              <volume>21</volume>
              <elocation-id>749</elocation-id>
              <history>
                <date date-type="received">
                  <day>28</day>
                  <month>4</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>12</day>
                  <month>8</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2020</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Breast cancer patients are at a four-fold increased risk of developing a venous thromboembolism (VTE), a major cause of death in this group. Conversely, coagulation factors promote tumour growth and metastasis. This has been evidenced in preclinical models, with an inhibitory effect of anticoagulants on cancer growth through proliferative, angiogenic, apoptotic, cancer stem cell and metastatic processes. The extrinsic clotting pathway is also more upregulated in patients in the relatively poorer prognosis oestrogen receptor (ER)-negative breast cancer subgroup, with increased tumour stromal expression of the coagulation factors Tissue Factor and thrombin.</p>
                  <p id="Par2">Rivaroxaban (XareltoÂ®, Bayer AG, Leverkusen, Germany) is a direct oral anticoagulant (DOAC). It is a Factor Xa inhibitor that is routinely prescribed for the prevention of stroke in non-valvular atrial fibrillation and for both VTE prophylaxis and treatment. This trial will assess the anti-proliferative and other anti-cancer progression mechanisms of Rivaroxaban in ER-negative early breast cancer patients.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par3">This UK-based preoperative window-of-opportunity phase II randomised control trial will randomise 88 treatment-naÃ¯ve early breast cancer patients to receive 20â€‰mg OD Rivaroxaban treatment for 11 to 17â€‰days or no treatment. Treatment will be stopped 24â€‰h (range 18â€“36â€‰h) prior to surgery or repeat core biopsy. All patients will be followed up for 2â€‰weeks following surgery or repeat core biopsy.</p>
                  <p id="Par4">The primary endpoint is change in tumour Ki67. Secondary outcome measures include tumour markers of apoptosis and angiogenesis, extrinsic clotting pathway activation and systemic markers of metastasis, tumour load and coagulation.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p id="Par5">Laboratory evidence supports an anti-cancer role for anticoagulants; however, this has failed to translate into survival benefit when trialled in patients with metastatic disease or poor prognosis cancers, such as lung cancer. Subgroup analysis supported a potential survival benefit in better prognosis advanced disease patients. This is the first study to investigate the anti-cancer effects of anticoagulants in early breast cancer.</p>
                </sec>
                <sec>
                  <title>Trial registration</title>
                  <p id="Par6">UK National Research Ethics Service (NRES) approval 15/NW/0406, MHRA Clinical Trials Authorisation 48380/0003/001-0001. The sponsor is Manchester University NHS Foundation Trust, and the trial is co-ordinated by Cancer Research UK Liverpool Cancer Trials Unit (LCTU). EudraCT <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004909-33/GB">2014-004909-33</ext-link>, registered 27 July 2015. <ext-link ext-link-type="uri" xlink:href="http://www.isrctn.com/ISRCTN14785273">ISRCTN14785273</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Tissue Factor</kwd>
                <kwd>Thrombin</kwd>
                <kwd>FXa</kwd>
                <kwd>DOAC</kwd>
                <kwd>NOAC</kwd>
                <kwd>Rivaroxaban</kwd>
                <kwd>Breast cancer</kwd>
                <kwd>Clinical trial</kwd>
                <kwd>Ki67</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000272</institution-id>
                      <institution>National Institute for Health Research</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>NIHR CS-11-014</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Kirwan</surname>
                      <given-names>Cliona C.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© The Author(s) 2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par47">Breast cancer in women is associated with a four-fold increased risk of venous thromboembolism (VTE) compared to age-matched women without cancer [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Chemotherapy-induced VTE occurs in up to 7% of early breast cancer and 17% of metastatic breast cancer patients [<xref ref-type="bibr" rid="CR3">3</xref>]. Breast cancer patients who develop VTE have a worse survival, which cannot solely be accounted for by VTE-induced mortality [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. It is thought to in part be due to a promotion of cancer growth and metastasis by coagulation factors.</p>
              <p id="Par48">Tissue Factor (TF), a transmembrane glycoprotein, is the initiator of the extrinsic clotting cascade. TF binds to plasma factor VII/VIIa (FVII/VIIa) to initiate coagulation via activation of Factor X (FX). This leads to the generation of thrombin, fibrin deposition and clot formation, as well as platelet activation (Fig.Â <xref rid="Fig1" ref-type="fig">1</xref>). In addition to its haemostatic role, TF activates cell signalling through TF:FVIIa and TF:FVIIa:FXa cleaving of the G-coupled protease-activated receptor (PARs) 1 and 2 complexes.
<fig id="Fig1"><label>Fig. 1</label><caption><p>The extrinsic coagulation pathway. Tissue Factor (TF), the main initiator of the coagulation cascade, complexes with Factor VIIa to activate Factor X, and in turn converts prothrombin (PT) to thrombin (Th) and ultimately fibrinogen to fibrin, with subsequent clot formation. FXa is inhibited by the direct oral anticoagulant Rivaroxaban. Thrombin also binds to protease-activated receptor 1 (PAR-1), and the TF/FVIIa/Xa complex to PAR-2. In cancer cells, this is proposed to result in pro-angiogenic, pro-proliferative and pro-invasive gene expression resulting in increased metastases. Figure created with BioRender.com [<xref ref-type="bibr" rid="CR6">6</xref>]. Abbreviations: TF, Tissue Factor; FVIIa, activated Factor VII; FX, Factor X; FXa, activated Factor X; PT, prothrombin; Th, thrombin; PAR, protease-activated receptor</p></caption><graphic xlink:href="13063_2020_4675_Fig1_HTML" id="MO1"/></fig></p>
              <p id="Par49">TF directly promotes tumour growth, migration and angiogenesis via activation of the PAR-2 receptor [<xref ref-type="bibr" rid="CR7">7</xref>â€“<xref ref-type="bibr" rid="CR11">11</xref>]. Thrombin can also modify tumour cell behaviour, directly through the activation of PAR receptors, indirectly by acting on stromal cells, or by the generation of fibrin matrices [<xref ref-type="bibr" rid="CR12">12</xref>â€“<xref ref-type="bibr" rid="CR14">14</xref>]. Thrombin promotes tumour growth in vitro [<xref ref-type="bibr" rid="CR15">15</xref>] and in vivo [<xref ref-type="bibr" rid="CR16">16</xref>â€“<xref ref-type="bibr" rid="CR18">18</xref>], enhances tumour adhesion to platelets [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>] and endothelial cells [<xref ref-type="bibr" rid="CR20">20</xref>] in vitro and increases experimental (tail-vein injection) metastasis [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Thrombin also increases tumour cell motility [<xref ref-type="bibr" rid="CR22">22</xref>]. TF [<xref ref-type="bibr" rid="CR23">23</xref>] and thrombin [<xref ref-type="bibr" rid="CR24">24</xref>] promote neo-angiogenesis via upregulation of VEGF (a potent angiogenic factor) in cancer cells through the PI3K/Akt pathway [<xref ref-type="bibr" rid="CR25">25</xref>]. TF also downregulates anti-angiogenic factors such as thrombospondin-1 and thrombospondin-2 [<xref ref-type="bibr" rid="CR26">26</xref>], while thrombin upregulates matrix metalloproteinase-2 [<xref ref-type="bibr" rid="CR27">27</xref>]. TF and thrombin also activate angiogenesis by clotting-dependent mechanisms through production (via thrombin) of polymerised fibrin which provides a scaffold around tumours to support and stimulate endothelial cell proliferation [<xref ref-type="bibr" rid="CR28">28</xref>]. In clinical studies, TF expression correlates with VEGF expression and markers of angiogenesis [<xref ref-type="bibr" rid="CR29">29</xref>], while prothrombin fragments (produced when prothrombin is converted to active thrombin) closely associate with areas of neo-angiogenesis at the tumour-stroma interface [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p>
              <p id="Par50">Cancer cells express high levels of TF, thrombin and PARs [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Breast cancer expression of TF has been reported to be an independent predictor of overall survival [<xref ref-type="bibr" rid="CR34">34</xref>]. Plasma D-dimer (fibrin degradation by-product) is increased in breast cancer and correlates with tumour stage, poor prognosis molecular phenotypes oestrogen receptor (ER) negative, human epidermal growth factor receptor 2 (HER-2) positive [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>], circulating tumour cells [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] and reduced survival [<xref ref-type="bibr" rid="CR39">39</xref>]. D-dimer also has potential as a pharmacodynamic biomarker for chemotherapy response [<xref ref-type="bibr" rid="CR40">40</xref>].</p>
              <p id="Par51">In a prospective cohort study of 248 early breast cancer patients, we found that tumour fibroblast expression of TF was increased in patients with primary breast cancer as compared to both ductal carcinoma in situ (DCIS) and normal breast. We also found that fibroblast TF, thrombin, PAR-1 and PAR-2 expression were increased in patients with ER-negative, HER-2-positive and high Ki67 tumours [<xref ref-type="bibr" rid="CR41">41</xref>].</p>
              <p id="Par52">Inhibition of this coagulation cascade could therefore be a therapeutic option in breast cancer patients. A Cochrane review in 2011 reported that parenteral anticoagulation (with either unfractionated heparin or low molecular weight heparin) for patients with cancer, who have no therapeutic or prophylactic indication for anticoagulation, resulted in a statistically and clinically significant reduction in mortality at 24â€‰months. This demonstrates a potential anti-cancer effect of anticoagulants in patients with better prognosis metastatic disease [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
              <p id="Par53">Direct oral anticoagulants (DOACs) inhibit thrombin (e.g. dabigatran etexilate (PradaxaÂ®)) or its activating enzyme Factor Xa (e.g. Rivaroxaban). DOACs have come into regular clinical use in the last decade for the prevention of VTE in orthopaedic surgery and of stroke in non-valvular atrial fibrillation [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. DOACs are also used for the treatment of primary or recurrent VTE. DOACs target a specific single enzyme within the extrinsic clotting pathway unlike the more widespread effects of heparins and vitamin K antagonists (Warfarin). A meta-analysis of randomised controlled trials of VTE-treatment with DOACs in cancer patients has indicated they are as safe and effective as conventional treatments [<xref ref-type="bibr" rid="CR45">45</xref>].</p>
              <p id="Par54">Rivaroxaban was the first orally active direct Factor Xa inhibitor and, through inhibition of the Tissue Factor-Factor VIIa-Factor Xa complex, inhibits the conversion of prothrombin to thrombin [<xref ref-type="bibr" rid="CR46">46</xref>]. Rivaroxaban is well absorbed from the gut and maximum inhibition of Factor Xa occurs 1 to 4Â h after administration [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Rivaroxaban has shown comparable safety to heparin for thromboprophylaxis after total hip replacements, with the convenience of oral dosing and reduced coagulation monitoring [<xref ref-type="bibr" rid="CR49">49</xref>]. Rivaroxaban has the potential to downregulate the TF-FVIIa-FXa complex activation of PAR-2 and the subsequent tumour cell migration and production of pro-angiogenic and immune-modulating cytokines, chemokines and growth factors [<xref ref-type="bibr" rid="CR10">10</xref>]. Rivaroxaban was chosen as the DOAC for this window-of-opportunity study as it inhibits the coagulation cascade at its origin and has a good safety profile. We have also found that Rivaroxaban inhibits cancer stem cell (CSC) activity in the in vitro functional CSC assay of mammosphere formation [<xref ref-type="bibr" rid="CR50">50</xref>].</p>
              <p id="Par55">In summary, in vitro and in vivo evidence supports a potential inhibitory effect of anticoagulants on cancer growth through proliferative, cancer stem cell, angiogenic and metastatic processes. ER-negative early breast cancer patients have a relatively poorer prognosis and higher stage at diagnosis with an associated reduced disease-free survival. ER-negative early breast cancer patients also have fewer options for adjuvant therapy. Our previous data supports the hypothesis that the extrinsic clotting pathway is more upregulated in the ER-negative breast cancer subgroup as compared to ER-positive breast cancer, and thereby provides a potential therapeutic strategy.</p>
              <p id="Par56">To test a novel therapy in the adjuvant breast cancer setting would require thousands of patients, long follow-up and great expense. The alternative is the more novel â€˜window-of-opportunityâ€™ clinical trial design where drugs are tested over a short period, in the preoperative setting. Biomarkers are used as early markers for response and long-term outcome. Ki67 (tumour proliferation marker) is recognised as such a marker in trials of endocrine therapy. Short-term neoadjuvant studies have demonstrated that only 2Â weeks of preoperative endocrine therapy induces changes in Ki67 which predicts for treatment benefit and long-term survival outcome [<xref ref-type="bibr" rid="CR51">51</xref>]. By using biomarkers, we may be able to demonstrate the potential effectiveness of an anticoagulant in the clinical setting to support future larger adjuvant trials.</p>
              <p id="Par57">The TIP Trial will assess the anti-proliferative and other anti-cancer progression mechanisms of Rivaroxaban in ER-negative early breast cancer patients.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <p id="Par58">This study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (AdditionalÂ fileÂ <xref rid="MOESM1" ref-type="media">1</xref>).</p>
              <sec id="Sec3">
                <title>Aim</title>
                <p id="Par59">The primary aim of the Thrombin Inhibition Preoperatively in Early Breast Cancer (TIP) trial is to determine whether preoperative administration of the oral Factor Xa inhibitor Rivaroxaban results in inhibition of tumour proliferation markers, as determined by a reduction in tumour Ki67 from baseline (pre-treatment) to post treatment (â€˜end-of-trialâ€™, at time of surgical excision or repeat core biopsy prior to neoadjuvant chemotherapy), in ER-negative early breast cancer patients.</p>
              </sec>
              <sec id="Sec4">
                <title>Study design</title>
                <p id="Par60">The TIP trial is a phase II preoperative window-of-opportunity randomised controlled trial of Rivaroxaban compared to no treatment in ER-negative stage Iâ€“III early breast cancer patients.</p>
                <p id="Par61">This UK-based multi-centre study will randomise 88 eligible patients (1:1) to either Rivaroxaban 20â€‰mg once daily (OD) or no treatment (control). Randomisation will be blinded to pathologists and data analysts, but not to patients or clinicians.</p>
              </sec>
              <sec id="Sec5">
                <title>Sample size calculation</title>
                <p id="Par62">The trial is designed with a two-sided alpha level of 0.05 and an estimated 80% power to detect a 0.6 standard deviation (SD) reduction in percentage tissue expression of Ki67 in early breast cancer patients treated with Rivaroxaban. Based on a two-sample <italic>t</italic> test with this 80% power, 88 eligible patients are required. We will allow for a 10% drop out rate, and therefore, 8 extra patients (giving a total of 96 patients) may need to be recruited. Any patient that withdraws from the trial or does not have surgery or a repeat core biopsy following treatment will be removed from the study and replaced.</p>
              </sec>
              <sec id="Sec6">
                <title>Participants</title>
                <p id="Par63">Females aged 18â€‰years or over with newly diagnosed early-stage breast cancer (stages Iâ€“III) that have a tumour of size â‰¥â€‰10â€‰mm and are oestrogen receptor negative (ERâˆ’) as defined by an ER QuickScore/Allred Scoreâ€‰â‰¤â€‰5 will be eligible to participate in the TIP trial. Exclusion criteria include factors related to slow drug excretion (e.g. poor renal function), drug interactions (e.g. azole-antimycotics) and risk factors for bleeding (e.g. recent major surgery).</p>
              </sec>
              <sec id="Sec7">
                <title>Screening for eligibility</title>
                <p id="Par64">Assessments for patient eligibility to participate in the trial are completed prior to patient randomisation. These include blood biochemistry, liver function tests, baseline tumour assessment as per National Health Service Breast Screening Programme guidelines [<xref ref-type="bibr" rid="CR52">52</xref>] and histopathological core biopsy including ER/PR receptor status. An electronic screening log is used to record each patient screened for the trial (even if not approached) and whether or not they were recruited.</p>
              </sec>
              <sec id="Sec8">
                <title>Randomisation</title>
                <p id="Par65">Patients will be randomly assigned (1:1) to either the control or intervention arm. Randomisation will be carried out centrally at the Liverpool Cancer Trials Centre (LCTC) based on pre-specified randomisation lists. The sequence of allocations is produced using the Stata package <italic>ralloc</italic> employing permutated block randomisation with block length of 4, 6 and 8. There are no stratification factors to be considered.</p>
              </sec>
              <sec id="Sec9">
                <title>Intervention group</title>
                <p id="Par66">Patients randomised to the intervention arm will receive Rivaroxaban 20â€‰mg once daily for 11â€“17â€‰days after diagnosis, prior to further treatment in the form of surgery or neo-adjuvant chemotherapy (NAC). Patients with planned NAC consent to undergo a repeat core biopsy once the trial treatment period has been completed.</p>
                <p id="Par67">Rivaroxaban treatment is stopped 24â€‰h (range 18â€“36â€‰h) prior to surgery or repeat core biopsy before commencing NAC (Figs.Â <xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref>). The dose of 20â€‰mg OD was chosen as this is the licenced dose in the UK for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors [<xref ref-type="bibr" rid="CR53">53</xref>]. No other concurrent neoadjuvant breast cancer or anticoagulant therapy is permitted.
<fig id="Fig2"><label>Fig. 2</label><caption><p>Thrombin Inhibition Preoperatively (TIP) in Early Breast Cancer Trial flow diagram. In this multi-centre study patients are randomised 1:1 20â€‰mg Rivaroxaban once daily (OD): No Treatment. Randomisation is blinded to pathologists, research laboratory staff and data analysts, but not to patients and clinicians</p></caption><graphic xlink:href="13063_2020_4675_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>TIP Trial Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure. Abbreviations: mg, milligram; OD, once daily</p></caption><graphic xlink:href="13063_2020_4675_Fig3_HTML" id="MO3"/></fig></p>
                <p id="Par68">All patients in the intervention arm will have an alert sticker placed in their notes to ensure that the medical team are aware that the patient has been anticoagulated and take all necessary precautions to minimise bleeding in the event of any residual anticoagulant effect.</p>
                <p id="Par69">Modifications to the rivaroxaban dose are not allowed; the intervention will simply be discontinued upon presentation with unacceptable toxicity.</p>
              </sec>
              <sec id="Sec10">
                <title>Control group</title>
                <p id="Par70">Patients randomised to the control group will not receive any anticoagulant therapy between diagnosis and either surgery or repeat biopsy prior to commencing NAC. They will receive current standard of care.</p>
                <p id="Par71">The use of a blinded placebo plus usual care comparator was considered in trial design but was decided against given the TIP trial has a biological endpoint (Ki67). Clinicians (surgeons or radiologists performing biopsies) are not to be blinded as a safety measure, but laboratory staff and data analysts will be blinded to avoid bias.</p>
              </sec>
              <sec id="Sec11">
                <title>Procedure</title>
                <p id="Par72">Following randomisation, all patients receive a copy of their signed consent form, a patient information sheet and a patient contact card. Residual tissue from the formalin-fixed paraffin-embedded pre-treatment diagnostic core biopsy tissue which is routinely stored will be requested for trial purposes and a 35-ml venous blood sample collected.</p>
                <p id="Par73">Upon termination of Rivaroxaban treatment or none, residual formalin-fixed and fresh tumour tissue will be obtained from trial patients undergoing surgery after routine clinical processing or from the repeat research biopsy prior to NAC.</p>
                <p id="Par74">All post-trial care, including provision for compensation, is through the NHS standard care pathway and NHS channels.</p>
              </sec>
              <sec id="Sec12">
                <title>Patient and public involvement</title>
                <p id="Par75">Patient and public representatives (PPI) were involved in the set-up of the trial, and a patient representative will take part in Trial Steering Committee meetings. PPI indicated to us that the trial risk was minimal and acceptable.</p>
              </sec>
              <sec id="Sec13">
                <title>Measures</title>
                <p id="Par76">Pathologists, research laboratory staff and data analysts will be blinded to patient randomisation in the TIP trial for assessment of both primary and secondary outcome measures.</p>
              </sec>
              <sec id="Sec14">
                <title>Primary outcome measure</title>
                <sec id="Sec15">
                  <title>Ki67</title>
                  <p id="Par77">The primary outcome measure of the TIP trial is to determine the absolute and percentage change in the tumour tissue expression of the biomarker Ki67 before and after Rivaroxaban treatment, with the control arm acting as a reference group.</p>
                  <p id="Par78">The completely specified primary outcome measure as defined by the five elements set out by Saldanha et al. [<xref ref-type="bibr" rid="CR54">54</xref>]: <italic>(1) Domain</italic>: Breast cancer tumour cell proliferation. <italic>(2) Specific measurement</italic>: Immunohistochemical assessment of the proportion (%) of cells staining for the nuclear antigen Ki67. <italic>(3) Metric</italic>: Absolute and percentage change from baseline. <italic>(4) Method of aggregation</italic>: Mean. <italic>(5) Time point</italic>: Post-treatment (â€˜end-of-trialâ€™, 14â€‰days range 11â€“17, at time of surgical excision or repeat core biopsy prior to neoadjuvant chemotherapy).</p>
                </sec>
              </sec>
              <sec id="Sec16">
                <title>Secondary outcome measures</title>
                <p id="Par79">A range of potential breast cancer pharmacodynamic biomarkers will be studied as secondary outcome measures:
<list list-type="order"><list-item><p id="Par80">Primary mammosphere formation assays will be performed ex vivo on fresh tumour tissue at the end-of-trial time-point to determine cancer stem cell activity. This data will be presented as a comparison of the means of mammosphere forming efficiency (MFE) in the intervention and control arms. MFE is calculated by dividing the number of mammospheres formed at 7â€‰days by the number of cells seeded [<xref ref-type="bibr" rid="CR55">55</xref>].</p></list-item><list-item><p id="Par81">Formalin-fixed paraffin-embedded (FFPE) tissue will be assessed for tumour markers of angiogenesis (CD31), apoptosis (Cleaved caspase 3, TUNEL) and the extrinsic clotting pathway (Tissue Factor, thrombin, PAR-1; in both epithelial cells/fibroblasts) by immunohistochemistry. Baseline core biopsy samples and end-of-trial biopsy samples will be assessed, and mean values analysed.</p></list-item><list-item><p id="Par82">Plasma biomarkers of coagulation (Tissue Factor, thrombin and d-dimer) will be quantified by enzyme-linked immunosorbent assay (ELISA) with the change from baseline to the end-of-trial time-point assessed. Mean biomarker will be compared between the control and intervention arms.</p></list-item><list-item><p id="Par83">FFPE tissue and plasma will be stored for future translational research, for example ctDNA, with patient consent.</p></list-item></list></p>
                <p id="Par84">Trial tumour tissue, plasma and serum samples, both for short-term storage and for future translational research, will be stored in temperature-controlled facilities at the Oglesby Cancer Research Building in Manchester, UK. This patient material will all be stored according to Good Clinical Laboratory Practise (GCLP) guidelines [<xref ref-type="bibr" rid="CR56">56</xref>].</p>
              </sec>
              <sec id="Sec17">
                <title>Analysis</title>
                <p id="Par85">Both primary and secondary analyses will be carried out on an intention to treat (ITT) basis. Missing data or missing patientsâ€™ samples will be minimised by active monitoring by the Trial Coordinator, regularly reviewed by the Trial Management Group (TMG), including scheduled data cleaning, sample checking and communications with trial sites. If samples for the primary endpoint analysis are not collected, the patient will be replaced. Any patients who withdraw from the trial will be replaced. If the level of missing data exceeds these safeguards, it may be handled by multiple imputation. Separate multiple imputations by treatment arm would be performed, using the method of chained equations.</p>
                <sec id="Sec18">
                  <title>Ki67</title>
                  <p id="Par86">Manual Section Score Ki67 will be compared between arms using a beta regression model including terms accounting for baseline Ki67, treatment arm, and covariates known to be associated with Ki67 such as tumour grade and HER-2 status. Although the sample size is based on a <italic>t</italic> test, a beta regression model for the analysis is superior, partly because the analysis would be on the original scale, partly because covariates including baseline would be easily accounted for and partly because treatment effects on variance could be explicitly modelled. Ki67 measurements will be performed in accordance with national guidance [<xref ref-type="bibr" rid="CR57">57</xref>].</p>
                </sec>
              </sec>
              <sec id="Sec19">
                <title>Data management</title>
                <p id="Par87">The paper Case Report Form (CRF) distributed by the LCTU is the primary data collection instrument for the study and is completed by delegated site staff. The accuracy of these CRFs are the responsibility of the Principal Investigator at each site. CRF data is entered into an electronic database manually from the paper forms by LCTU staff. There is central monitoring by the LCTU to ensure that any data collected is compliant with the trial protocol. The database used for this trial includes validation features which will alert the user to certain inconsistent or missing data on data entry. Data stored at the LCTU will be checked for missing or unusual values (range checks) and checked for consistency over time. The LCTU will preserve the confidentiality of participants taking part in the study. Access to the final trial dataset is granted by the written authorisation of the Chief Investigator, CCK.</p>
              </sec>
              <sec id="Sec20">
                <title>Participant retention and complete follow-up</title>
                <p id="Par88">The Trial Coordinator will produce reports on patient withdrawals, losses to follow-up and the quantity of missing CRFs/data across sites for review by LCTU business meetings, the Trial Management Group (TMG), Trial Steering Committee (TSC) and Independent Safety and Data Monitoring Committee (ISDMC). Any problems identified will be discussed and remedial action taken as necessary. Patients who withdraw from the trial will be replaced, and any who deviate will be managed on a case-by-case basis.</p>
                <p id="Par89">If a patient wishes to withdraw from trial treatment, this will be acted upon immediately and will cause no detrimental effect to them in receiving usual standard of care. Following end of study biopsy, a single safety follow-up is performed at ~â€‰2/52. There is no long-term follow-up within the trial. All long-term follow-up will be as per usual NHS practice.</p>
              </sec>
              <sec id="Sec21">
                <title>Trial governance</title>
                <sec id="Sec22">
                  <title>Trial Coordinator (LCTU)</title>
                  <p id="Par90">The LCTU will conduct central monitoring to ensure patient safety and that the trial procedures, trial intervention administration and laboratory and data collection processes meet both Sponsor and regulatory requirements. This includes ensuring that all regulatory and ethical approvals are in place before a site is opened, and generation of periodic Central Monitoring Reports for review by the Trial Management Group (TMG). The LCTU will carry out audits of trial sites and laboratories independent of the investigators and the Sponsor using set procedures after the first patient is recruited and after the tenth patient is recruited. The LCTU has a formalised Quality Management System in place for trial Quality Assurance.</p>
                </sec>
                <sec id="Sec23">
                  <title>Trial Management Group</title>
                  <p id="Par91">The Trial Management Group (TMG) will comprise of the Chief Investigator, other lead investigators (clinical and non-clinical) and members of the LCTU. The TMG will be responsible for the day-to-day running and management of the trial and will meet approximately three times per year.</p>
                </sec>
                <sec id="Sec24">
                  <title>Trial Steering Committee</title>
                  <p id="Par92">The Trial Steering Committee (TSC) includes a minimum of an independent Chairman; two additional independent expert members in the field of breast cancer (one being a statistician) and a lay/consumer representative, along with members of the Trial Management Group (TMG). Among other things, the TSC takes responsibility for monitoring and supervising the progress of the trial, considering recommendations from the Independent Safety and Data Monitoring Committee (IDSMC) and advising the TMG on all aspects of the trial as outlined in the TSC charter. Further details on the TIP Trial TSC charter can be obtained from the Trial Coordinator (<ext-link ext-link-type="uri" xlink:href="https://www.lctu.org.uk">https://www.lctu.org.uk</ext-link>).</p>
                  <p id="Par93">The ultimate decision for the continuation of the trial lies with the TSC, and the TSC may stop the trial before completion upon recommendation of the IDSMC.</p>
                </sec>
                <sec id="Sec25">
                  <title>Independent Data and Safety Monitoring Committee</title>
                  <p id="Par94">The TIP Trial Independent Safety and Data Monitoring Committee (IDSMC) is a multidisciplinary group independent from the Sponsor and competing interests. The IDSMC consists of an independent chairperson with breast cancer and/or significant trial experience, plus two further independent members: one statistician and at least one clinician. They are responsible for safeguarding the interests of trial participants, with interim monitoring of the safety and efficacy of the interventions during the trial, and for monitoring the overall progress and conduct of the clinical trial as outlined in the IDSMC charter. Further details on the TIP Trial IDSMC charter can be obtained from the Trial Coordinator.</p>
                  <p id="Par95">The IDSMC will first convene prior to the recruitment of the first patient and will then define the required frequency of subsequent meetings (at least annually). The IDSMC will provide a recommendation to the Trial Steering Committee concerning the continuation of the study.</p>
                </sec>
              </sec>
              <sec id="Sec26">
                <title>Safety monitoring</title>
                <p id="Par96">Rivaroxaban is an oral anticoagulant, with an associated risk of bleeding, as with any anticoagulant. Unlike Warfarin, blood monitoring is not required. We will systemically collect data on all expected and unexpected adverse events at each study visit, with Principal Investigators required to assess and report them to the Trial Coordinator throughout the whole trial process, from trial entry through to follow-up. An adverse event term must be provided for each adverse event, using the terms listed in the Common Terminology Criteria for Adverse Events v4.03 [<xref ref-type="bibr" rid="CR58">58</xref>]. Investigators must report serious adverse events (SAEs) within 24â€‰h of the local site becoming aware of the event. Adverse events related to the study intervention will be reported in trial publications.</p>
                <p id="Par97">This study may be terminated at the request of the Chief Investigator, Independent Data and Safety Monitoring Committee or the Independent Ethics Committee if, during the course of the study, concerns about the safety emerge. Serious adverse events are relayed directly to the Chief Investigator via the Trial Coordinator, with all adverse events included in the Central Monitoring Reports reviewed at Trial Management Group meetings. Interim monitoring of safety is also carried out by the IDSMC. The report of a serious adverse reaction or multiple adverse reaction incidences (depending on severity) would constitute grounds for trial termination.</p>
              </sec>
              <sec id="Sec27">
                <title>Dissemination</title>
                <p id="Par98">We aim to present the data at scientific and medical conferences and to publish the results in a peer-reviewed journal. Authorship guidelines will be as per Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly work in Medical Journals, International Committee of Medical Journal Editors (ICMJE) [<xref ref-type="bibr" rid="CR59">59</xref>]. We have no intended use of professional writers.</p>
              </sec>
            </sec>
            <sec id="Sec28">
              <title>Discussion</title>
              <p id="Par99">Ki67 is recognised as a marker of tumour proliferation in trials of endocrine therapy. Short-term neoadjuvant studies have demonstrated that only 2Â weeks of preoperative endocrine therapy induces changes in Ki67 which predicts for treatment benefit and long-term survival outcome [<xref ref-type="bibr" rid="CR51">51</xref>]. By using biomarkers, we will be able to demonstrate the effectiveness of Rivaroxaban in the clinical setting within 5Â years, thereby providing an improved clinical trials service to the patients recruited. However, the measurement of Ki67 has its challenges as there is substantial heterogeneity and variable levels of validity in methods of assessment [<xref ref-type="bibr" rid="CR57">57</xref>]. It is agreed that we will use the immunohistochemistry (IHC) method for determining Ki67 percentages. The IHC staining and assessment of Ki67 will be performed on all trial samples in one batch upon trial completion in an attempt to minimise variability and increase accuracy.</p>
              <p id="Par100">The collection of fresh tumour tissue for mammosphere analysis will not always be feasible, particularly in patients with smaller tumours or who undergo a research biopsy. Mammosphere analysis is therefore a secondary and exploratory outcome of the TIP trial. However, if successful, it may allow assessment of the value of fresh tissue in ex vivo analysis as a biomarker of response.</p>
              <p id="Par101">This trial has been designed to minimise the chance of haematoma following surgery or biopsy in the presence of an anticoagulant. The terminal elimination half-life of Rivaroxaban is 5 to 9â€‰h in healthy subjects aged 20 to 45â€‰years and 11 to 13â€‰h in elderly patients aged 60 to 76â€‰years [<xref ref-type="bibr" rid="CR60">60</xref>]. Clinical guidelines recommend stopping the drug in routine surgery patients at â‰¥â€‰24â€‰h before surgery for minor risk procedures [<xref ref-type="bibr" rid="CR61">61</xref>]; therefore, a safe time period, in patients with normal renal function, was taken as 24â€‰h. However, clinicians (surgeons or radiologists performing biopsies) are still advised of the randomisation so bleeding precautions can be maximised.</p>
              <p id="Par102">The trial was initially designed as a window-of-opportunity pre-surgery study; however, with changing clinical practice, increasingly ER-negative patients are having neoadjuvant chemotherapy. Therefore, an amendment to the study was submitted to allow inclusion of neoadjuvant patients, with the post-trial biopsy being an additional research biopsy. It is routine to undergo radiological clip placement prior to commencement of chemotherapy, to allow identification of the tumour bed in the presence of complete radiological response to NAC. Therefore, to minimise impact on trial patients, the post-trial biopsy is performed at the time of clip placement. This was assessed as acceptable by our patient and public collaborators.</p>
              <sec id="Sec29">
                <title>Trial status</title>
                <p id="Par103">Current protocol: Version 6, dated 10 October 2017</p>
                <p id="Par104">Important protocol modifications are communicated to relevant parties by the trial coordinator by direct communication and via the LCTU Portal <ext-link ext-link-type="uri" xlink:href="http://www.lctu.org.uk">www.lctu.org.uk</ext-link>.</p>
                <p id="Par105">Recruitment start: June 2016</p>
                <p id="Par106">Expected recruitment end: September 2020</p>
                <p id="Par107">Open trial centres: Wythenshawe Hospital (Manchester), Royal Bolton Hospital, Royal Liverpool University Hospital, North Manchester General Hospital, St Jamesâ€™s University Hospital Leeds, Arrow Park Hospital/Clatterbridge Cancer Centre (Wirral), Churchill Hospital (Oxford); all United Kingdom.</p>
                <p id="Par108">Trial sponsor contact: Hayley Brooks, Oncology Clinical Trials Manager, Manchester University NHS Foundation Trust, Hayley.brooks@mft.nhs.uk</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary information</title>
              <sec id="Sec30">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="13063_2020_4675_MOESM1_ESM.pdf">
                      <caption>
                        <p><bold>Additional file 1.</bold> SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>ABS</term>
                  <def>
                    <p id="Par7">Association of Breast Surgery</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CD31</term>
                  <def>
                    <p id="Par8">Cluster of differentiation 31</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DOAC</term>
                  <def>
                    <p id="Par9">Direct oral anticoagulant (synonym: NOAC)</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DOI</term>
                  <def>
                    <p id="Par10">Digital Object Identifier</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ECCO</term>
                  <def>
                    <p id="Par11">European Cancer Organisation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ELISA</term>
                  <def>
                    <p id="Par12">Enzyme-linked immunosorbent assay</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ER</term>
                  <def>
                    <p id="Par13">Oestrogen receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EudraCT</term>
                  <def>
                    <p id="Par14">European Clinical Trials Database Reference</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FFPE</term>
                  <def>
                    <p id="Par15">Formalin-fixed paraffin-embedded</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FVII</term>
                  <def>
                    <p id="Par16">Factor VII (seven)</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FVIIa</term>
                  <def>
                    <p id="Par17">Activated Factor VII (seven)</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FX</term>
                  <def>
                    <p id="Par18">Factor X (ten)</p>
                  </def>
                </def-item>
                <def-item>
                  <term>FXa</term>
                  <def>
                    <p id="Par19">Activated Factor X (ten)</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GP</term>
                  <def>
                    <p id="Par20">General Practitioner</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HER2</term>
                  <def>
                    <p id="Par21">Human epidermal growth factor receptor 2</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IDSMC</term>
                  <def>
                    <p id="Par22">Independent Data and Safety Monitoring Committee</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ISRCTN</term>
                  <def>
                    <p id="Par23">International Standard Randomised Controlled Trials Number</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ITT</term>
                  <def>
                    <p id="Par24">Intension to treat</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LCTC</term>
                  <def>
                    <p id="Par25">Liverpool Cancer Trials Centre</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LCTU</term>
                  <def>
                    <p id="Par26">Cancer Research UK Liverpool Cancer Trials Unit</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MCRC</term>
                  <def>
                    <p id="Par27">Manchester Cancer Research Centre</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MFE</term>
                  <def>
                    <p id="Par28">Mammosphere Forming Efficiency</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MG</term>
                  <def>
                    <p id="Par29">Milligram</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MHRA</term>
                  <def>
                    <p id="Par30">Medicines and Healthcare Products Regulatory Agency</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NAC</term>
                  <def>
                    <p id="Par31">Neoadjuvant chemotherapy</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NIHR</term>
                  <def>
                    <p id="Par32">National Institute for Health Research</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NOAC</term>
                  <def>
                    <p id="Par33">Novel oral anticoagulant (synonym: DOAC)</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NRES</term>
                  <def>
                    <p id="Par34">National Research Ethics Service</p>
                  </def>
                </def-item>
                <def-item>
                  <term>OD</term>
                  <def>
                    <p id="Par35">Once daily</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PAR</term>
                  <def>
                    <p id="Par36">(1/2) protease activated receptor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PPI</term>
                  <def>
                    <p id="Par37">Patient and public input</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PT</term>
                  <def>
                    <p id="Par38">Prothrombin</p>
                  </def>
                </def-item>
                <def-item>
                  <term>REC</term>
                  <def>
                    <p id="Par39">Research Ethics Committee</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TF</term>
                  <def>
                    <p id="Par40">Tissue Factor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TIP</term>
                  <def>
                    <p id="Par41">Thrombin Inhibition Preoperatively in Early Breast Cancer</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TMG</term>
                  <def>
                    <p id="Par42">Trial Management Group</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TSC</term>
                  <def>
                    <p id="Par43">Trial Steering Committee</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TUNEL</term>
                  <def>
                    <p id="Par44">Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling</p>
                  </def>
                </def-item>
                <def-item>
                  <term>VEGF</term>
                  <def>
                    <p id="Par45">Vascular endothelial growth factor</p>
                  </def>
                </def-item>
                <def-item>
                  <term>VTE</term>
                  <def>
                    <p id="Par46">Venous thromboembolism</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisherâ€™s Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary information</title>
              <p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13063-020-04675-7.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>The TIP Trial is coordinated by Helen Scott from the LCTU, with support from Manchester University NHS Foundation Trust Sponsor representative Hayley Brook. Sample collection is supported by the MCRC Biobank.</p>
              <p>The Principal Investigators at each trial site are Cliona Kirwan (Wythenshawe Hospital), Christopher Holcombe (Royal Liverpool University Hospital), Angela Volleamere (Royal Bolton Hospital), Maria Bramley (North Manchester General Hospital), Jalal Kokan (Macclesfield District General Hospital), Pankaj Gupta Roy (Oxford Churchill Hospital), Rajgopal Achuthan (St Jamesâ€™s University Hospital Leeds) and Raman Vinayagam (Clatterbridge Hospital Wirral).</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authorsâ€™ contributions</title>
              <p>CCK, JC and EB were the major contributors in writing the manuscript. SC provided statistical guidance for the trial. All authors read and approved the final abstract.</p>
              <sec id="FPar1">
                <title>Authorsâ€™ information</title>
                <p id="Par109">CCK is a Clinician Scientist in Surgical Oncology, Royal College of Surgeons of England Professor of Surgical Trials and Consultant Oncoplastic Breast Surgeon based at the Manchester Cancer Research Centre, with clinical work at The Nightingale Centre at Wythenshawe Hospital, UK. She is the Chief Investigator of the TIP trial and may be contacted for Public and Scientific Queries at cliona.kirwan@manchester.ac.uk.</p>
              </sec>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This trial is funded by a National Institute for Health Research (NIHR) Clinician Scientist award and the NIHR Clinical Research Network. It is supported by The University of Manchester, the Association of Breast Surgery (ABS) and a European Cancer Organisation (ECCO) Fellowship Grant (Joint ECCO-AACR-EORTC-ESMO Workshop â€˜Methods in Clinical cancer Researchâ€™). Ultimate authority in the study design, collection, management, analysis, interpretation of data, writing of the report and the decision to submit the report for publication remains with the Chief Investigator CCK.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>Access to the final trial dataset will be granted by the written authorisation of the Chief Investigator, CCK.</p>
            </notes>
            <notes id="FPar2">
              <title>Ethics approval and consent to participate</title>
              <p id="Par110">This study has UK National Research Ethics Service (NRES) approval REC reference 15/NW/0406 from the North West - Liverpool Central Research Ethics Committee. Patients must give written informed consent via the document-controlled trial consent form before undergoing any trial-specific screening investigations. Trial sites are responsible for assessing a patientâ€™s capability to give informed consent and ensuring an appropriate member of staff has countersigned and dated the consent form. Patients with planned NAC must consent to undergo a repeat core biopsy once treatment has been completed. Patients will be asked to consent that data are recorded, collected, stored and processed in accordance with the EU Data Protection Directive (95/46/EC). Patients at consent may give permission for stored tissue and/or blood samples to be used for future breast cancer research, which is optional for TIP trial participation. The TIP trial coordinator confirms that eligibility criteria are met, that informed consent is obtained and that these are both documented.</p>
              <p id="Par111">This study may be terminated at the request of the Chief Investigator, Independent Data and Safety Monitoring Committee or the Independent Ethics Committee if, during the course of the study, concerns about the safety emerge.</p>
            </notes>
            <notes id="FPar3">
              <title>Consent for publication</title>
              <p id="Par112">Not applicable. No intended sharing of deidentified individual clinical trial participant-level data (IPD).</p>
            </notes>
            <notes id="FPar4" notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par113">The authors declare that they have no competing interests.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walker</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Card</surname>
                      <given-names>TR</given-names>
                    </name>
                    <name>
                      <surname>West</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Crooks</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Grainge</surname>
                      <given-names>MJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases</article-title>
                  <source>Eur J Cancer</source>
                  <year>2013</year>
                  <volume>49</volume>
                  <issue>6</issue>
                  <fpage>1404</fpage>
                  <lpage>1413</lpage>
                  <?supplied-pmid 23146958?>
                  <pub-id pub-id-type="pmid">23146958</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cronin-Fenton</surname>
                      <given-names>DP</given-names>
                    </name>
                    <name>
                      <surname>Sondergaard</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Pedersen</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Fryzek</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Cetin</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Acquavella</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006</article-title>
                  <source>Br J Cancer</source>
                  <year>2010</year>
                  <volume>103</volume>
                  <issue>7</issue>
                  <fpage>947</fpage>
                  <lpage>953</lpage>
                  <?supplied-pmid 20842120?>
                  <pub-id pub-id-type="pmid">20842120</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kirwan</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>McDowell</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>McCollum</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>Kumar</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>GJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer</article-title>
                  <source>Br J Cancer</source>
                  <year>2008</year>
                  <volume>99</volume>
                  <issue>7</issue>
                  <fpage>1000</fpage>
                  <lpage>1006</lpage>
                  <?supplied-pmid 18766191?>
                  <pub-id pub-id-type="pmid">18766191</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jones</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Stockton</surname>
                      <given-names>DL</given-names>
                    </name>
                    <name>
                      <surname>Simpson</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Murchison</surname>
                      <given-names>JT</given-names>
                    </name>
                  </person-group>
                  <article-title>Idiopathic venous thromboembolic disease is associated with a poorer prognosis from subsequent malignancy</article-title>
                  <source>Br J Cancer</source>
                  <year>2009</year>
                  <volume>101</volume>
                  <issue>5</issue>
                  <fpage>840</fpage>
                  <lpage>842</lpage>
                  <?supplied-pmid 19654574?>
                  <pub-id pub-id-type="pmid">19654574</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kirwan</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>McDowell</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>McCollum</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>GJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Incidence of venous thromboembolism during chemotherapy for breast cancer: impact on cancer outcome</article-title>
                  <source>Anticancer Res</source>
                  <year>2011</year>
                  <volume>31</volume>
                  <issue>6</issue>
                  <fpage>2383</fpage>
                  <lpage>2388</lpage>
                  <?supplied-pmid 21737669?>
                  <pub-id pub-id-type="pmid">21737669</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <mixed-citation publication-type="other">BioRender, a web-based tool for life-science and medical illustration. Toronto, Canada. Available from: <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">https://biorender.com/</ext-link>. Accessed 16 Apr 2020.</mixed-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ahamed</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Versteeg</surname>
                      <given-names>HH</given-names>
                    </name>
                    <name>
                      <surname>Kerver</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Mueller</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Hogg</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Disulfide isomerization switches tissue factor from coagulation to cell signaling</article-title>
                  <source>Proc Natl Acad Sci U S A</source>
                  <year>2006</year>
                  <volume>103</volume>
                  <issue>38</issue>
                  <fpage>13932</fpage>
                  <lpage>13937</lpage>
                  <?supplied-pmid 16959886?>
                  <pub-id pub-id-type="pmid">16959886</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ruf</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Tissue factor and cancer</article-title>
                  <source>Thromb Res</source>
                  <year>2012</year>
                  <volume>130</volume>
                  <issue>Suppl 1</issue>
                  <fpage>S84</fpage>
                  <lpage>S87</lpage>
                  <?supplied-pmid 23026674?>
                  <pub-id pub-id-type="pmid">23026674</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Morris</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Ding</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Ricks</surname>
                      <given-names>TK</given-names>
                    </name>
                    <name>
                      <surname>Gullapalli</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Wolfe</surname>
                      <given-names>BL</given-names>
                    </name>
                    <name>
                      <surname>Trejo</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells</article-title>
                  <source>Cancer Res</source>
                  <year>2006</year>
                  <volume>66</volume>
                  <issue>1</issue>
                  <fpage>307</fpage>
                  <lpage>314</lpage>
                  <?supplied-pmid 16397244?>
                  <pub-id pub-id-type="pmid">16397244</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kasthuri</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Taubman</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Mackman</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of tissue factor in cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2009</year>
                  <volume>27</volume>
                  <issue>29</issue>
                  <fpage>4834</fpage>
                  <lpage>4838</lpage>
                  <?supplied-pmid 19738116?>
                  <pub-id pub-id-type="pmid">19738116</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hjortoe</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Petersen</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Albrektsen</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Sorensen</surname>
                      <given-names>BB</given-names>
                    </name>
                    <name>
                      <surname>Norby</surname>
                      <given-names>PL</given-names>
                    </name>
                    <name>
                      <surname>Mandal</surname>
                      <given-names>SK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration</article-title>
                  <source>Blood</source>
                  <year>2004</year>
                  <volume>103</volume>
                  <issue>8</issue>
                  <fpage>3029</fpage>
                  <lpage>3037</lpage>
                  <?supplied-pmid 15070680?>
                  <pub-id pub-id-type="pmid">15070680</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coughlin</surname>
                      <given-names>SR</given-names>
                    </name>
                  </person-group>
                  <article-title>Thrombin signalling and protease-activated receptors</article-title>
                  <source>Nature</source>
                  <year>2000</year>
                  <volume>407</volume>
                  <issue>6801</issue>
                  <fpage>258</fpage>
                  <lpage>264</lpage>
                  <?supplied-pmid 11001069?>
                  <pub-id pub-id-type="pmid">11001069</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Coughlin</surname>
                      <given-names>SR</given-names>
                    </name>
                  </person-group>
                  <article-title>Protease-activated receptors in hemostasis, thrombosis and vascular biology</article-title>
                  <source>J Thromb Haemost</source>
                  <year>2005</year>
                  <volume>3</volume>
                  <issue>8</issue>
                  <fpage>1800</fpage>
                  <lpage>1814</lpage>
                  <?supplied-pmid 16102047?>
                  <pub-id pub-id-type="pmid">16102047</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mosesson</surname>
                      <given-names>MW</given-names>
                    </name>
                  </person-group>
                  <article-title>Fibrinogen and fibrin structure and functions</article-title>
                  <source>J Thromb Haemost</source>
                  <year>2005</year>
                  <volume>3</volume>
                  <issue>8</issue>
                  <fpage>1894</fpage>
                  <lpage>1904</lpage>
                  <?supplied-pmid 16102057?>
                  <pub-id pub-id-type="pmid">16102057</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zain</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>YQ</given-names>
                    </name>
                    <name>
                      <surname>Feng</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Nierodzik</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Karpatkin</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Concentration-dependent dual effect of thrombin on impaired growth/apoptosis or mitogenesis in tumor cells</article-title>
                  <source>Blood</source>
                  <year>2000</year>
                  <volume>95</volume>
                  <issue>10</issue>
                  <fpage>3133</fpage>
                  <lpage>3138</lpage>
                  <?supplied-pmid 10807779?>
                  <pub-id pub-id-type="pmid">10807779</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nierodzik</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Plotkin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kajumo</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Karpatkin</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo</article-title>
                  <source>J Clin Invest</source>
                  <year>1991</year>
                  <volume>87</volume>
                  <issue>1</issue>
                  <fpage>229</fpage>
                  <lpage>236</lpage>
                  <?supplied-pmid 1845869?>
                  <pub-id pub-id-type="pmid">1845869</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nierodzik</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Kajumo</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Karpatkin</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo</article-title>
                  <source>Cancer Res</source>
                  <year>1992</year>
                  <volume>52</volume>
                  <issue>12</issue>
                  <fpage>3267</fpage>
                  <lpage>3272</lpage>
                  <?supplied-pmid 1596884?>
                  <pub-id pub-id-type="pmid">1596884</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nierodzik</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Takeshita</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>YQ</given-names>
                    </name>
                    <name>
                      <surname>Feng</surname>
                      <given-names>XS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis</article-title>
                  <source>Blood</source>
                  <year>1998</year>
                  <volume>92</volume>
                  <issue>10</issue>
                  <fpage>3694</fpage>
                  <lpage>3700</lpage>
                  <?supplied-pmid 9808563?>
                  <pub-id pub-id-type="pmid">9808563</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wojtukiewicz</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Tang</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Nelson</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Walz</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Diglio</surname>
                      <given-names>CA</given-names>
                    </name>
                    <name>
                      <surname>Honn</surname>
                      <given-names>KV</given-names>
                    </name>
                  </person-group>
                  <article-title>Thrombin enhances tumor cell adhesive and metastatic properties via increased alpha IIb beta 3 expression on the cell surface</article-title>
                  <source>Thromb Res</source>
                  <year>1992</year>
                  <volume>68</volume>
                  <issue>3</issue>
                  <fpage>233</fpage>
                  <lpage>245</lpage>
                  <?supplied-pmid 1281930?>
                  <pub-id pub-id-type="pmid">1281930</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Klepfish</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Greco</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Karpatkin</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix</article-title>
                  <source>Int J Cancer</source>
                  <year>1993</year>
                  <volume>53</volume>
                  <issue>6</issue>
                  <fpage>978</fpage>
                  <lpage>982</lpage>
                  <?supplied-pmid 8473056?>
                  <pub-id pub-id-type="pmid">8473056</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wojtukiewicz</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Tang</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Ciarelli</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Nelson</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Walz</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Diglio</surname>
                      <given-names>CA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Thrombin increases the metastatic potential of tumor cells</article-title>
                  <source>Int J Cancer</source>
                  <year>1993</year>
                  <volume>54</volume>
                  <issue>5</issue>
                  <fpage>793</fpage>
                  <lpage>806</lpage>
                  <?supplied-pmid 7686887?>
                  <pub-id pub-id-type="pmid">7686887</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Asanuma</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Wakabayashi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Hayashi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Okuyama</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Seto</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Matsumine</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis</article-title>
                  <source>Oncology</source>
                  <year>2004</year>
                  <volume>67</volume>
                  <issue>2</issue>
                  <fpage>166</fpage>
                  <lpage>173</lpage>
                  <?supplied-pmid 15539922?>
                  <pub-id pub-id-type="pmid">15539922</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhang</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Ding</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Shao</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Hao</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <article-title>Regulation of vascular endothelial growth factor (VEGF) production and angiogenesis by tissue factor (TF) in SGC-7901 gastric cancer cells</article-title>
                  <source>Cancer Biol Ther</source>
                  <year>2005</year>
                  <volume>4</volume>
                  <issue>7</issue>
                  <fpage>769</fpage>
                  <lpage>772</lpage>
                  <?supplied-pmid 15846107?>
                  <pub-id pub-id-type="pmid">15846107</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Schuff-Werner</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Steiner</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Thrombin/thrombin receptor (PAR-1)-mediated induction of IL-8 and VEGF expression in prostate cancer cells</article-title>
                  <source>Biochem Biophys Res Commun</source>
                  <year>2006</year>
                  <volume>343</volume>
                  <issue>1</issue>
                  <fpage>183</fpage>
                  <lpage>189</lpage>
                  <?supplied-pmid 16530725?>
                  <pub-id pub-id-type="pmid">16530725</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Karar</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Maity</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>PI3K/AKT/mTOR pathway in angiogenesis</article-title>
                  <source>Front Mol Neurosci</source>
                  <year>2011</year>
                  <volume>4</volume>
                  <fpage>51</fpage>
                  <?supplied-pmid 22144946?>
                  <pub-id pub-id-type="pmid">22144946</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yu</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>May</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lhotak</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Shahrzad</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Shirasawa</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Weitz</surname>
                      <given-names>JI</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis</article-title>
                  <source>Blood</source>
                  <year>2005</year>
                  <volume>105</volume>
                  <issue>4</issue>
                  <fpage>1734</fpage>
                  <lpage>1741</lpage>
                  <?supplied-pmid 15494427?>
                  <pub-id pub-id-type="pmid">15494427</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Maragoudakis</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Kraniti</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Giannopoulou</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Alexopoulos</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Matsoukas</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Modulation of angiogenesis and progelatinase a by thrombin receptor mimetics and antagonists</article-title>
                  <source>Endothelium</source>
                  <year>2001</year>
                  <volume>8</volume>
                  <issue>3</issue>
                  <fpage>195</fpage>
                  <lpage>205</lpage>
                  <?supplied-pmid 11824472?>
                  <pub-id pub-id-type="pmid">11824472</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>van Hinsbergh</surname>
                      <given-names>VW</given-names>
                    </name>
                    <name>
                      <surname>Collen</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Koolwijk</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of fibrin matrix in angiogenesis</article-title>
                  <source>Ann N Y Acad Sci</source>
                  <year>2001</year>
                  <volume>936</volume>
                  <fpage>426</fpage>
                  <lpage>437</lpage>
                  <?supplied-pmid 11460496?>
                  <pub-id pub-id-type="pmid">11460496</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carneiro-Lobo</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Lima</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Mariano-Oliveira</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Dutra-Oliveira</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Oba-Shinjo</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Marie</surname>
                      <given-names>SK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growth factor and interleukin-8 in human astrocytoma patients</article-title>
                  <source>Oncol Rep</source>
                  <year>2014</year>
                  <volume>31</volume>
                  <issue>2</issue>
                  <fpage>679</fpage>
                  <lpage>686</lpage>
                  <?supplied-pmid 24297570?>
                  <pub-id pub-id-type="pmid">24297570</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wojtukiewicz</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Rucinska</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zimnoch</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Jaromin</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Piotrowski</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Rozanska-Kudelska</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Expression of prothrombin fragment 1+2 in cancer tissue as an indicator of local activation of blood coagulation</article-title>
                  <source>Thromb Res</source>
                  <year>2000</year>
                  <volume>97</volume>
                  <issue>5</issue>
                  <fpage>335</fpage>
                  <lpage>342</lpage>
                  <?supplied-pmid 10709909?>
                  <pub-id pub-id-type="pmid">10709909</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wojtukiewicz</surname>
                      <given-names>MZ</given-names>
                    </name>
                    <name>
                      <surname>Sierko</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Zacharski</surname>
                      <given-names>LR</given-names>
                    </name>
                    <name>
                      <surname>Zimnoch</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Kudryk</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Kisiel</surname>
                      <given-names>W</given-names>
                    </name>
                  </person-group>
                  <article-title>Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer</article-title>
                  <source>Semin Thromb Hemost</source>
                  <year>2003</year>
                  <volume>29</volume>
                  <issue>3</issue>
                  <fpage>291</fpage>
                  <lpage>300</lpage>
                  <?supplied-pmid 12888933?>
                  <pub-id pub-id-type="pmid">12888933</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rak</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Milsom</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>May</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Klement</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy</article-title>
                  <source>Semin Thromb Hemost</source>
                  <year>2006</year>
                  <volume>32</volume>
                  <issue>1</issue>
                  <fpage>54</fpage>
                  <lpage>70</lpage>
                  <?supplied-pmid 16479463?>
                  <pub-id pub-id-type="pmid">16479463</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hu</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Campbell</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Perez-Soler</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Karpatkin</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Role of endogenous thrombin in tumor implantation, seeding, and spontaneous metastasis</article-title>
                  <source>Blood</source>
                  <year>2004</year>
                  <volume>104</volume>
                  <issue>9</issue>
                  <fpage>2746</fpage>
                  <lpage>2751</lpage>
                  <?supplied-pmid 15265791?>
                  <pub-id pub-id-type="pmid">15265791</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ueno</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Toi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Koike</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Nakamura</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tominaga</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration</article-title>
                  <source>Br J Cancer</source>
                  <year>2000</year>
                  <volume>83</volume>
                  <issue>2</issue>
                  <fpage>164</fpage>
                  <lpage>170</lpage>
                  <?supplied-pmid 10901365?>
                  <pub-id pub-id-type="pmid">10901365</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blackwell</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Haroon</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Broadwater</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Berry</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Harris</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Iglehart</surname>
                      <given-names>JD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status</article-title>
                  <source>J Clin Oncol</source>
                  <year>2000</year>
                  <volume>18</volume>
                  <issue>3</issue>
                  <fpage>600</fpage>
                  <lpage>608</lpage>
                  <?supplied-pmid 10653875?>
                  <pub-id pub-id-type="pmid">10653875</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Blackwell</surname>
                      <given-names>KL</given-names>
                    </name>
                    <name>
                      <surname>Dewhirst</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Liotcheva</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Snyder</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Broadwater</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Bentley</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2004</year>
                  <volume>10</volume>
                  <issue>12 Pt 1</issue>
                  <fpage>4083</fpage>
                  <lpage>4088</lpage>
                  <?supplied-pmid 15217943?>
                  <pub-id pub-id-type="pmid">15217943</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mego</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zuo</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Gao</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>EN</given-names>
                    </name>
                    <name>
                      <surname>Giordano</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Tin</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer</article-title>
                  <source>Thromb Haemost</source>
                  <year>2015</year>
                  <volume>113</volume>
                  <issue>3</issue>
                  <fpage>593</fpage>
                  <lpage>598</lpage>
                  <?supplied-pmid 25373787?>
                  <pub-id pub-id-type="pmid">25373787</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <mixed-citation publication-type="other">Kirwan CC, Descamps T, Castle J. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer. Clin Transl Oncol. 2019;22(6):870â€“7.</mixed-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Batschauer</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Figueiredo</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Bueno</surname>
                      <given-names>EC</given-names>
                    </name>
                    <name>
                      <surname>Ribeiro</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Dusse</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Fernandes</surname>
                      <given-names>AP</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer</article-title>
                  <source>Ann Oncol</source>
                  <year>2010</year>
                  <volume>21</volume>
                  <issue>6</issue>
                  <fpage>1267</fpage>
                  <lpage>1272</lpage>
                  <?supplied-pmid 19880435?>
                  <pub-id pub-id-type="pmid">19880435</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kirwan</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>McCollum</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>McDowell</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Byrne</surname>
                      <given-names>GJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Investigation of proposed mechanisms of chemotherapy-induced venous thromboembolism: endothelial cell activation and procoagulant release due to apoptosis</article-title>
                  <source>Clin Appl Thromb Hemost</source>
                  <year>2015</year>
                  <volume>21</volume>
                  <issue>5</issue>
                  <fpage>420</fpage>
                  <lpage>427</lpage>
                  <?supplied-pmid 25748178?>
                  <pub-id pub-id-type="pmid">25748178</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shaker</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Bundred</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Landberg</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Pritchard</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Albadry</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Nicholson</surname>
                      <given-names>SL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Breast cancer stromal clotting activation (Tissue Factor and thrombin): a pre-invasive phenomena that is prognostic in invasion</article-title>
                  <source>Cancer Med</source>
                  <year>2020</year>
                  <volume>9</volume>
                  <issue>5</issue>
                  <fpage>1768</fpage>
                  <lpage>1778</lpage>
                  <?supplied-pmid 31962001?>
                  <pub-id pub-id-type="pmid">31962001</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <mixed-citation publication-type="other">Akl EA, Gunukula S, Barba M, Yosuico VE, van Doormaal FF, Kuipers S, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. 2011;(4):CD006652. 10.1002/14651858.CD006652.pub3.</mixed-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cohen</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Hamilton</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bird</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Horblyuk</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis</article-title>
                  <source>PLoS One</source>
                  <year>2016</year>
                  <volume>11</volume>
                  <issue>8</issue>
                  <fpage>e0160064</fpage>
                  <?supplied-pmid 27487187?>
                  <pub-id pub-id-type="pmid">27487187</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lip</surname>
                      <given-names>GY</given-names>
                    </name>
                    <name>
                      <surname>Mitchell</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>LZ</given-names>
                    </name>
                    <name>
                      <surname>Phatak</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Kachroo</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Relative efficacy and safety of non-vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups</article-title>
                  <source>Int J Cardiol</source>
                  <year>2016</year>
                  <volume>204</volume>
                  <fpage>88</fpage>
                  <lpage>94</lpage>
                  <?supplied-pmid 26655548?>
                  <pub-id pub-id-type="pmid">26655548</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vedovati</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Germini</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Agnelli</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Becattini</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis</article-title>
                  <source>Chest</source>
                  <year>2015</year>
                  <volume>147</volume>
                  <issue>2</issue>
                  <fpage>475</fpage>
                  <lpage>483</lpage>
                  <?supplied-pmid 25211264?>
                  <pub-id pub-id-type="pmid">25211264</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roehrig</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Straub</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Pohlmann</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lampe</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Pernerstorfer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Schlemmer</surname>
                      <given-names>KH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor</article-title>
                  <source>J Med Chem</source>
                  <year>2005</year>
                  <volume>48</volume>
                  <issue>19</issue>
                  <fpage>5900</fpage>
                  <lpage>5908</lpage>
                  <?supplied-pmid 16161994?>
                  <pub-id pub-id-type="pmid">16161994</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kubitza</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Becka</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Voith</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Zuehlsdorf</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wensing</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor</article-title>
                  <source>Clin Pharmacol Ther</source>
                  <year>2005</year>
                  <volume>78</volume>
                  <issue>4</issue>
                  <fpage>412</fpage>
                  <lpage>421</lpage>
                  <?supplied-pmid 16198660?>
                  <pub-id pub-id-type="pmid">16198660</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kubitza</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Becka</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Wensing</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Voith</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Zuehlsdorf</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects</article-title>
                  <source>Eur J Clin Pharmacol</source>
                  <year>2005</year>
                  <volume>61</volume>
                  <issue>12</issue>
                  <fpage>873</fpage>
                  <lpage>880</lpage>
                  <?supplied-pmid 16328318?>
                  <pub-id pub-id-type="pmid">16328318</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eriksson</surname>
                      <given-names>BI</given-names>
                    </name>
                    <name>
                      <surname>Borris</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Dahl</surname>
                      <given-names>OE</given-names>
                    </name>
                    <name>
                      <surname>Haas</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Huisman</surname>
                      <given-names>MV</given-names>
                    </name>
                    <name>
                      <surname>Kakkar</surname>
                      <given-names>AK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement</article-title>
                  <source>Circulation</source>
                  <year>2006</year>
                  <volume>114</volume>
                  <issue>22</issue>
                  <fpage>2374</fpage>
                  <lpage>2381</lpage>
                  <?supplied-pmid 17116766?>
                  <pub-id pub-id-type="pmid">17116766</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Castle</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Farnie</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Kirwan</surname>
                      <given-names>CC</given-names>
                    </name>
                  </person-group>
                  <article-title>PO-11 - Thrombin and cancer stem-like cells: in vitro support for breast cancer anticoagulation</article-title>
                  <source>Thromb Res</source>
                  <year>2016</year>
                  <volume>140</volume>
                  <issue>Suppl 1</issue>
                  <fpage>S180</fpage>
                  <?supplied-pmid 27161699?>
                  <pub-id pub-id-type="pmid">27161699</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dowsett</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>IE</given-names>
                    </name>
                    <name>
                      <surname>Ebbs</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Dixon</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Skene</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Griffith</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2005</year>
                  <volume>11</volume>
                  <issue>2 Pt 2</issue>
                  <fpage>951s</fpage>
                  <lpage>958s</lpage>
                  <?supplied-pmid 15701892?>
                  <pub-id pub-id-type="pmid">15701892</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <mixed-citation publication-type="other">Pathology reporting of breast disease in surgical excision specimens incorporating the dataset for histological reporting of breast cancer. The Royal College of Pathologists; 2016. <ext-link ext-link-type="uri" xlink:href="https://www.rcpath.org/uploads/assets/7763be1c-d330-40e8-95d08f955752792a/G148_BreastDataset-hires-Jun16.pdf:">https://www.rcpath.org/uploads/assets/7763be1c-d330-40e8-95d08f955752792a/G148_BreastDataset-hires-Jun16.pdf:</ext-link>. Accessed 17 Apr 2020.</mixed-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Khoury</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Adcock</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Symanowski</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Tiefenbacher</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Goodman</surname>
                      <given-names>O</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer</article-title>
                  <source>Am J Clin Pathol</source>
                  <year>2010</year>
                  <volume>134</volume>
                  <issue>6</issue>
                  <fpage>964</fpage>
                  <lpage>969</lpage>
                  <?supplied-pmid 21088161?>
                  <pub-id pub-id-type="pmid">21088161</pub-id>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saldanha</surname>
                      <given-names>IJ</given-names>
                    </name>
                    <name>
                      <surname>Dickersin</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Outcomes in Cochrane systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability</article-title>
                  <source>PLoS One</source>
                  <year>2014</year>
                  <volume>9</volume>
                  <issue>10</issue>
                  <fpage>e109400</fpage>
                  <?supplied-pmid 25329377?>
                  <pub-id pub-id-type="pmid">25329377</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shaw</surname>
                      <given-names>FL</given-names>
                    </name>
                    <name>
                      <surname>Harrison</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Spence</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ablett</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Simoes</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Farnie</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A detailed mammosphere assay protocol for the quantification of breast stem cell activity</article-title>
                  <source>J Mammary Gland Biol Neoplasia</source>
                  <year>2012</year>
                  <volume>17</volume>
                  <issue>2</issue>
                  <fpage>111</fpage>
                  <lpage>117</lpage>
                  <?supplied-pmid 22665270?>
                  <pub-id pub-id-type="pmid">22665270</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ezzelle</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez-Chavez</surname>
                      <given-names>IR</given-names>
                    </name>
                    <name>
                      <surname>Darden</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Stirewalt</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kunwar</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Hitchcock</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories</article-title>
                  <source>J Pharm Biomed Anal</source>
                  <year>2008</year>
                  <volume>46</volume>
                  <issue>1</issue>
                  <fpage>18</fpage>
                  <lpage>29</lpage>
                  <?supplied-pmid 18037599?>
                  <pub-id pub-id-type="pmid">18037599</pub-id>
                </element-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dowsett</surname>
                      <given-names>M</given-names>
                    </name>
                    <collab>Nielsen TO</collab>
                    <name>
                      <surname>A'Hern</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bartlett</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Coombes</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Cuzick</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Assessment of Ki67 in breast cancer: recommendations from the international Ki67 in breast cancer working group</article-title>
                  <source>J Natl Cancer Inst</source>
                  <year>2011</year>
                  <volume>103</volume>
                  <issue>22</issue>
                  <fpage>1656</fpage>
                  <lpage>1664</lpage>
                  <?supplied-pmid 3216967?>
                  <pub-id pub-id-type="pmid">21960707</pub-id>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <mixed-citation publication-type="other">National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Available from: <ext-link ext-link-type="uri" xlink:href="https://evs.nci.nih.gov/ftp1/CTCAE/About.html">https://evs.nci.nih.gov/ftp1/CTCAE/About.html</ext-link>. Accessed 22 July 2020.</mixed-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <mixed-citation publication-type="other">(ICMJE) ICoMJE. Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly work in Medical Journals. Available from: <ext-link ext-link-type="uri" xlink:href="http://icmje.org/recommendations">http://icmje.org/recommendations</ext-link>. Accessed 22 July 2020.</mixed-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <mixed-citation publication-type="other">National Institute for Clinical Excellence (NICE) Rivaroxaban Indications and Dose. Available from: <ext-link ext-link-type="uri" xlink:href="https://bnf.nice.org.uk/drug/rivaroxaban.html#indicationsAndDoses">https://bnf.nice.org.uk/drug/rivaroxaban.html#indicationsAndDoses</ext-link>. Accessed 11 July 2019.</mixed-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lai</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Davidson</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Galloway</surname>
                      <given-names>SW</given-names>
                    </name>
                    <name>
                      <surname>Thachil</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Perioperative management of patients on new oral anticoagulants</article-title>
                  <source>Br J Surg</source>
                  <year>2014</year>
                  <volume>101</volume>
                  <issue>7</issue>
                  <fpage>742</fpage>
                  <lpage>749</lpage>
                  <?supplied-pmid 24777590?>
                  <pub-id pub-id-type="pmid">24777590</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
